Understanding Unanticipated Problems (UPs) Elizabeth Ness, RN, MS Director, Staff Development Office of the Clinical Director Center for Cancer Research,

Slides:



Advertisements
Similar presentations
Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Advertisements

Chicken Soup for the Busy Coordinator September 2009.
What is a Data and Safety Monitoring Plan and how do I get one? Presented by Office of Human Research Protection.
Protocol Deviations : Identification, Responses and Solutions The Office of Human Subjects Research’s Compliance Monitoring Program Educational Seminars:
UNANTICIPATED PROBLEMS INVOLVING RISKS TO SUBJECTS OR OTHERS & INCIDENTS OF NON-COMPLIANCE ( AKA PROTOCOL DEVIATIONS ) TRACY RIGHTMER, JD, CIP COMPLIANCE.
SOP Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Santiago, Chile August.
Unanticipated Problems Involving Risk to Subjects or Others (UPIRSO) Roy R. Estrada, PhD, PA-C, CIP Associate Director IRB UTHSCSA.
Reporting Unanticipated Problems Involving Risk to Subjects or Others and Adverse Events WFUHS Policy/Procedure Effective Date 6/1/07 Wendy Murray Monitoring.
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
Capturing and Reporting Adverse Events in Clinical Research
Reportable Events in Research Nancy C. LeGros Vinson & Elkins LLP Houston, TX Nancy C. LeGros Vinson & Elkins LLP Houston, TX
IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.
Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
CUMC IRB Investigator Meeting Human Subjects Research Non-Compliance September 15, 2005.
Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.
Renewing An Approved Protocol: IRB Review Process
Vanderbilt Human Research Protections Program
HRPP Policies & Forms Created/Revised for AAHRPP.
Unlocking the Mystery of General Information Reporting Research Compliance Administration Training Presentation Wednesday, June 6, 2007 Presenter:Heather.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Case Studies.
Defining Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Continuing Review VA Requirements Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst Program for Research Integrity Development and Education (PRIDE)
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
AAHRPP Accreditation Karen L. Smarr, PhD Human Research Compliance Officer Truman VA Hospital, Columbia, MO Cincinnati, OH March 19, 2007.
Paula Peyrani, MD Division of Infectious Diseases University of Louisville Performing the Study.
Month, day, year Reporting Adverse Events What, When, How? Cynthia Gross Professor, College of Pharmacy and School of Nursing The MN Center for Health.
Reporting Unanticipated Problems and Adverse Events: A Change in Policy Mary A. Banks RN, BS, BSN Director, BUMC IRB Wednesday, November 14, 2007.
Unanticipated Problems Potentially Involving Risks to Subjects or Others Research Protections Office Serving UVM and FAHC Updated April 2012.
New Adverse Event Reporting Policy Effective September 1, 2007.
Reporting Adverse Events and Unanticipated Problems to the UAB IRB Policy and Procedure Change September 22, 2006 Amanda G. Murphy, RN, CIP Assistant Director,
Office of Research Oversight ORO Reporting Adverse Events in Research to ORO Paula Squire Waterman, MS, CIP Department of Veterans Affairs Office of Research.
Sara Brand Associate Director Research Compliance Administration.
Investigational New Drug Application (IND)
EMORY INSTITUTIONAL REVIEW BOARD VERSION Unanticipated Problems, Protocol Deviations and Non-Compliance.
Michelle Groy Johnson Quality Improvement Officer Research Integrity Office Tough Love: Understanding the Purpose and Processes of Quality Assurance.
Adverse Event/Unanticipated Problems Policy and Procedures November 2007.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Research Studies GOTCHA’S By Sally Duffy. Failure to follow protocol, investigator agreements and regulations Did not use device/drug in manner specified.
Planning for Data and Safety Monitoring: Developing Your Study-specific DSMP OCR/GCRC Clinical Research Seminar November 15 th, 2006 Mary-Tara Roth, RN,
1 Unanticipated problems Melody Lin, Ph.D. December,
Continuing Review Presented by: Karen Jeans, PhD, CCRN, CIP Program Analyst, COACH.
VHA Research Compliance Reporting Requirements ORD Accreditation Conference Call December 15, 2011.
Case Studies: Puzzles in Human Research Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst, Program for Research Integrity Development and Education.
HRPP Policies & Forms Chapter Two Created/Revised for AAHRPP June 1, 2007.
Michelle Groy Johnson Quality Improvement Officer Research Integrity Office Houston, We have a Problem: When and How to Report Problems to the IRB.
Non-compliance with Human Subjects Research Regulations J. Bruce Smith, MD, CIP November 2014 Continuing Education for IRB Members.
GEORGIA STATE UNIVERSITY IRB ADAPTED FROM DHHS GUIDANCE ON UNANTICIPATED PROBLEMS Unanticipated Problems.
Main Line Hospitals Institutional Review Board Unanticipated Problems Anne Marie Hobson, BSN, JD, ORA Director Theresa Greaves, ORA Manager.
Slide 1 Standard Operating Procedures. Slide 2 Goal To review the standard operating procedures Creating the informed consent document Obtaining informed.
Bussara Sukpanichnant, Human Subject Protection Office, USAMD-AFRIMS Unanticipated Problems 15 th FERCAP International Conference 24 Nov 15 Nagasaki, Japan.
Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Dartmouth Human Research Protection Program (HRPP) Data Safety Monitoring and Reporting requirements Brown Bag Series: Noon / First Tuesday of the Month.
IRB reporting updates.
What is a Data and Safety Monitoring Plan and how do I get one?
Reportable Events & Other IRB Updates February 2017
Adverse Event Reporting: Trials and Tribulations
Pharmacovigilance in clinical trials
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Navigating Non-Compliance
SERIOUS ADVERSE EVENTS REPORTING
Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
IRB Prompt Reporting Requirements
UVM Research Protections Office
HHS Reporting Requirements and Adverse Events
Event Reporting in Human Subjects Research
Policy on Prompt Reporting
Presentation transcript:

Understanding Unanticipated Problems (UPs) Elizabeth Ness, RN, MS Director, Staff Development Office of the Clinical Director Center for Cancer Research, NCI

Objectives Define what an unanticipated problem is. Describe 2 examples of an unanticipated problem that is also an adverse event. Describe 2 examples of an unanticipated problem that is also a protocol violation. Describe 2 examples of an unanticipated problem that is not an AE or a protocol violation. Discuss potential correction plans for unanticipated problems. Describe who should be notified of an unanticipated problem.

Unanticipated Problem: Definition An incident, experience, or outcome that meets ALL of the following criteria: 1.Nature, severity, or frequency is unexpected for the subject population or research activities as described in the current IRB approved protocol, supporting documents, and the IC document(s) 2.Related or possibly related to participation in the research 3.Suggests the research may place the subject or others at a greater risk of harm (e.g., physical, psychological, economic, or social harm than previously recognized)

Applicable Regulations 45 CFR (b)(5) – written procedures for ensuring prompt reporting to IRB, appropriate institution officials… (i) any unanticipated problems involving risks to subjects or others… 21 CFR (b) – Follow written procedure for ensuring prompt reporting to the IRB, appropriate institutional officials, and FDA of (1) any unanticipated problems involving risks to human subjects or others;…. 21 CFR – ….The investigator shall also assure that he or she will promptly report to the IRB…and all unanticipated problems involving risk to human subjects or others, ….

Application Guidance Documents OHRP – Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events, January 15, 2007 – FDA – Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs — Improving Human Subject Protection, January 2009 – n/Guidances/UCM pdf n/Guidances/UCM pdf

Unanticipated Problems Algorithm An incident, experience, or outcome Is incident, experience, or outcome unexpected in nature, severity, or frequency? Is incident, experience, or outcome related or possibly related to participation in the research? Does the incident, experience, or outcome suggest that the research places subjects or others at a greater risk of physical or psychological harm than was previously known or recognized? The incident, experience, or outcome is an unanticipated problem The incident, experience, or outcome is not an unanticipated problem YES NO

Unanticipated Problem that is also an Adverse Event… Chronic reflux disease study is evaluating a new investigational agent that blocks acid release in the stomach. Two weeks after being randomized and started on the study intervention, subject develops acute kidney failure (increase in creatinine from BL of 1.0 mg/dl to 5.0 mg/dl). Further work-up reveals no other obvious cause for acute renal failure. The investigator concludes that the episode of acute renal failure probably was due to the investigational agent. Known risk profile of the investigational agent does not include renal toxicity, and the IRB-approved protocol and informed consent document for the study does not identify kidney damage as a risk of the research.

…Unanticipated Problem that is also an Adverse Event… Subjects with coronary artery disease presenting with unstable angina are enrolled in a multicenter clinical trial evaluating the safety and efficacy of an investigational vascular stent. Based on prior studies in animals and humans, the investigators anticipate that up to 5% of subjects receiving the investigational stent will require emergency coronary artery bypass graft (CABG) surgery because of acute blockage of the stent that is unresponsive to non-surgical interventions. The risk of needing emergency CABG surgery is described in the IRB-approved protocol and informed consent document. After the first 20 subjects are enrolled in the study, an interim analysis notes that 10 subjects (50%) have needed an emergency CABG soon after placement of the investigational stent. The rate at which subjects have needed to undergo CABG greatly exceeds the expected rate.

…Unanticipated Problem that is also an Adverse Event Behavioral study involves completion of a detailed survey asking questions about early childhood experiences. During the completion of the survey, one subject experiences sadness and depressed mood that resolved without intervention after a few hours. Protocol and informed consent document did not describe any risk of such negative psychological reactions. The investigator determines that the subject’s negative psychological reaction resulted from certain survey questions that triggered repressed memories of physical abuse as a child.

Unanticipated Problem that is also a Protocol Violation Malfunctioning infusion pump results in study drug being given over 15 minutes versus 1 hour as specified in protocol Ineligible patient who receives protocol intervention and experiences no adverse events Subject received more drug (10-times) than per protocol but suffers no adverse events

Unanticipated Problem that is not an AE or Protocol Violation Individually identifiable sensitive information stored on laptop computer without encryption, and the laptop computer is stolen Product contamination with no adverse events experienced by subjects Staff member becomes ill due to odor from IV bag of investigational product but patient with no adverse events

Once an UP is Identified, What Happens Next – Step 1 Develop corrective action plan which can include any of the following: Revise protocol: – Modify inclusion or exclusion criteria to mitigate the newly identified risks – Implement additional procedures for monitoring subjects Suspend enrollment of new subjects Terminate the research Informed consent – Revise the IC document Provide additional information about newly recognized risks to previously enrolled subjects – Inform enrolled subjects Increase monitoring activities Encrypt laptops, no identifiable information on laptop Provide training/re-training Work with appropriate institutional officials to correct problem

Once an UP is Identified, What Happens Next – Step 2a Unanticipated problems must be reported to the IRB. The report must include the following: Appropriate identifying information for the research protocol, such as the title, investigator’s name, and the IRB project number Detailed description of the adverse event, incident, experience, or outcome Explanation of the basis for determining that the adverse event, incident, experience, or outcome represents an unanticipated problem Description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the unanticipated problem

Once an UP is Identified, What Happens Next – Step 2b Reporting to the IRB must be done “promptly” Type of Unanticipated Problem Reporting Timeline to IRB Unanticipated problems that are serious adverse events (SAE) Within 1 week of the investigator becoming aware of the event Any unanticipated problem that is not a SAE Within 2 weeks of the investigator becoming aware of the problem Based on OHRP Guidance

Once an UP is Identified, What Happens Next – Step 3 Also consider reporting UP to: – CC via Occurrence Reporting System (ORS) – IND/IDE Sponsor Meets criteria for IND/IDE Safety reporting by sponsor to FDA OHRP recommends that ALL UPs should be reported to appropriate institutional officials, supporting agency, and OHRP within 1 month of the IRB’s receipt of the report of the problem from the investigator.

Unanticipated Problem Reporting OHSRP NIH IRB OHRP Investigator CC ORSSponsor FDA

Additional Resources OHRP Video (25 minutes) – MAS Policy: Occurrence Reports – MAS Policy: Identification and Management of Sentinel Events –

NCI IRB Unanticipated Problem Reporting via iRIS New: Unanticipated Problem Submission Form Updated: – Expedited Adverse Event and Follow-ups Added UP questions – Deviation Violation Submission Form Added UP questions – CR Form CTCAE TermGrade# of Events since last CR Total # of Events Attribution to Research Serious?Unexpected?